Low back pain can be stubbornly mysterious. For millions of people, the ache persists for years, even when doctors can’t find ...

Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...

Teva Pharmaceutical Industries Ltd. TEVA announced that the FDA has approved its biosimilar to Amgen’s AMGN blockbuster drug, ...

The FDA approval for Ponlimsi is based on comprehensive evidence, including analytical and clinical data.

Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia ® (denosumab), to treat a variety of ...

A health watchdog has approved the first new osteoporosis drug of its kind for more than a decade, after medics urged it to perform a U-turn. Earlier this year, more than 100 experts wrote a letter ...

The US Food and Drug Administration (FDA) has added a boxed warning to the label of the osteoporosis drug denosumab (Prolia) about increased risk for severe hypocalcemia in patients with advanced ...

A research team from the Department of Pharmacology and Pharmacy, LKS Faculty of Medicine of the University of Hong Kong ...

Prevention of osteoporosis should be considered before a bone break occurs, and many patients at risk for the chronic bone condition may benefit from pharmacologic options. "Most current guidelines ...

Study Links GLP-1 Use to Higher Risk of Bone Conditions and Gout . The team analyzed electronic health records from people ...